Drug Trial Radar · NCT07163624
UBT251 Injection Phase II (Type 2 Diabetes Mellitus) Study
Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
211
Actual
Start
Mar 22, 2025
Primary completion
Nov 21, 2025
Study completion Dec 30, 2025
Sponsor
- Lead sponsor
- The United Bio-Technology (Hengqin) Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Sep 9, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy of UBT251 injection after 24 weeks of continuous administration in patients with type 2 diabetes mellitus and to recommend the dosing regimen for the Phase III clinical trial.
Conditions
- Type 2 Diabetes Mellitus (T2DM)
Interventions
UBT251 Injection 2.0 mg and UBT251 Injection PlaceboDrug
UBT251 Injection and UBT251 Injection Placebo once weekly
UBT251 Injection 4.0 mg (ID 0.5 mg) and UBT251 Injection PlaceboDrug
UBT251 Injection and UBT251 Injection Placebo once weekly
UBT251 Injection 4.0 mg (ID 1.0 mg) and UBT251 Injection PlaceboDrug
UBT251 Injection and UBT251 Injection Placebo once weekly
UBT251 Injection 6.0 mg and UBT251 Injection PlaceboDrug
UBT251 Injection and UBT251 Injection Placebo once weekly
Semaglutide Injection (Ozempic®)Drug
Semaglutide Injection (Ozempic®) once weekly
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in HbA1c at Week 24Time frame: Baseline to week 24
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The United Bio-Technology (Hengqin) Co., Ltd.
Zhuhai, Guangdong, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.